Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.71 per share which met the analyst consensus estimate. This is a 7.79 percent decrease over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $3.88 billion which missed the analyst consensus estimate of $3.93 billion by 1.17 percent. This is a 5.27 percent decrease over sales of $4.10 billion the same period last year.
Teva Pharmaceutical Indus Q4 EPS $0.71, Inline, Sales $3.88B Miss $3.93B Estimate
Teva Pharmaceutical Indus (NYSE:TEVA) reported quarterly earnings of $0.71 per share which met the analyst consensus estimate. This is a 7.79 percent decrease over earnings of $0.77 per share from the same period last
Related Posts
ANI Pharmaceuticals Sees FY23 Adjusted EPS of $2.09-$2.59 Vs. Consensus Of $2.62; Forecasts Revenues Of $360M-$385M Vs. $352.49M Estimate
2023 Cortrophin specific revenue guidance is between $80.0 million to $90.0 million, representing 92% to 116% growth as compared to $41.7 million recognized in
‘Qatar Is Said To Prepare Imminent Bid For Manchester United FC’ – Bloomberg News
https://www.bloomberg.com/news/articles/2023-02-13/qatar-is-said-to-prepare-imminent-bid-for-manchester-united-fc?sref=TBDibEcD
Looking Into AMC Entertainment Hldgs’s Return On Capital Employed
During Q1, AMC Entertainment Hldgs (NYSE:AMC) brought in sales totaling $148.30 million. However, earnings decreased 55.88%, resulting in a loss of $427.80 million. AMC Entertainment Hldgs collected $162.50 million in revenue during Q4, but reported earnings showed a $969.60 million loss.